Literature DB >> 35305244

Reply to "Letter to the editor regarding 'Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis'".

Alessio Giuseppe Morganti1,2, Gabriella Macchia3, Francesco Deodato3,4, Donato Pezzulla5, Savino Cilla6, Milena Ferro3, Milly Buwenge1,2.   

Abstract

Entities:  

Keywords:  Oligometastases; Prostate cancer; Radiosurgery; Stereobody radiotherapy

Mesh：

Year:  2022        PMID： 35305244     DOI： 10.1007/s12094-022-02813-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  9 in total

1.  Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.

Authors:  Anna Katharina Seitz; Isabel Rauscher; Bernhard Haller; Markus Krönke; Sophia Luther; Matthias M Heck; Thomas Horn; Jürgen E Gschwend; Markus Schwaiger; Matthias Eiber; Tobias Maurer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-28       Impact factor: 9.236

2.  68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.

Authors:  Christian Schmidkonz; Michael Cordes; Daniela Schmidt; Tobias Bäuerle; Theresa Ida Goetz; Michael Beck; Olaf Prante; Alexander Cavallaro; Michael Uder; Bernd Wullich; Peter Goebell; Torsten Kuwert; Philipp Ritt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-03       Impact factor: 9.236

3.  Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.

Authors:  Cem Onal; Gokhan Ozyigit; Zuleyha Akgun; Banu Atalar; Sefik Igdem; Ezgi Oymak; Fulya Agaoglu; Ugur Selek; Ozan Cem Guler; Pervin Hurmuz; Teuto Zoto Mustafayev; Fadil Akyol
Journal:  Clin Nucl Med       Date:  2021-06-01       Impact factor: 7.794

4.  Reply to "Letter to the editor regarding 'Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis'".

Authors:  Alessio Giuseppe Morganti; Gabriella Macchia; Francesco Deodato; Donato Pezzulla; Savino Cilla; Milena Ferro; Milly Buwenge
Journal:  Clin Transl Oncol       Date:  2022-03-19       Impact factor: 3.405

5.  Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness.

Authors:  Rosario Mazzola; Giulio Francolini; Luca Triggiani; Giuseppe Napoli; Francesco Cuccia; Luca Nicosia; Lorenzo Livi; Stefano Maria Magrini; Matteo Salgarello; Filippo Alongi
Journal:  Clin Genitourin Cancer       Date:  2020-08-06       Impact factor: 2.872

6.  Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trial.

Authors:  Francesco Deodato; Savino Cilla; Gabriella Macchia; Luciana Caravatta; Samantha Mignogna; Mariangela Massaccesi; Vincenzo Picardi; Cinzia Digesu; Giuseppina Sallustio; Pierluigi Bonomo; Angelo Piermattei; Gabriella Ferrandina; Giovanni Scambia; Vincenzo Valentini; Numa Cellini; Alessio G Morganti
Journal:  Oncol Lett       Date:  2013-03-29       Impact factor: 2.967

7.  Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.

Authors:  René Baumann; Mark Koncz; Ulf Luetzen; Fabian Krause; Juergen Dunst
Journal:  Strahlenther Onkol       Date:  2017-11-27       Impact factor: 3.621

8.  [68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

Authors:  Jonathan Kuten; David Sarid; Ofer Yossepowitch; Nicola J Mabjeesh; Einat Even-Sapir
Journal:  EJNMMI Res       Date:  2019-08-29       Impact factor: 3.138

9.  Progression-free survival in patients with 68Ga-PSMA-PET-directed SBRT for lymph node oligometastases.

Authors:  Anita M Werensteijn-Honingh; Anne F J Wevers; Max Peters; Petra S Kroon; Martijn Intven; Wietse S C Eppinga; Ina M Jürgenliemk-Schulz
Journal:  Acta Oncol       Date:  2021-07-29       Impact factor: 4.089
  9 in total
  2 in total

1.  Letter to the editor regarding 'Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY‑2 clinical trial subanalysis'.

Authors:  Cem Onal; Ezgi Oymak
Journal:  Clin Transl Oncol       Date:  2022-03-03       Impact factor: 3.405

2.  Reply to "Letter to the editor regarding 'Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis'".

Authors:  Alessio Giuseppe Morganti; Gabriella Macchia; Francesco Deodato; Donato Pezzulla; Savino Cilla; Milena Ferro; Milly Buwenge
Journal:  Clin Transl Oncol       Date:  2022-03-19       Impact factor: 3.405
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.